Preparation of amino silane magnetic nanocomposite by the sol–gel process and investigation of its antibacterial activity

Micro & nano letters

article

Raana Hatami¹  Alireza Allafchian²  Fathallah Karimzadeh¹  Mohammad Hosein Enayati¹ 

[1] Department of Materials Engineering, Isfahan University of Technology;Research Institute for Nanotechnology and Advanced Materials, Isfahan University of Technology

关键词: sol-gel processing;    filled polymers;    field emission electron microscopy;    visible spectra;    crystal morphology;    nanofabrication;    microorganisms;    antibacterial activity;    X-ray diffraction;    nanomedicine;    coatings;    scanning electron microscopy;    transmission electron microscopy;    nanomagnetics;    ultraviolet spectra;    nanoparticles;    magnetic particles;    nanocomposites;    silver;    light scattering;    Fourier transform infrared spectra;    biomagnetism;    amino silane magnetic nanocomposite;    antibacterial activity;    magnetic characteristics;    silver nanoparticles;    tetraethyl orthosilicate;    antibacterial properties;    TEOS-APTES polymer;    magnetic core;    TEOS-APTES surface;    polymer nanocomposite;    magnetic properties;    polymer surface;    (3-aminopropyl) triethoxysilane;    sol-gel method;    field-emission scanning electron microscopy;    transmission electron microscopy;    amino silane magnetic nanocomposites;    Staphylococcus aureus;    Bacillus cereus;    Gram-positive bacteria;    Gram-negative bacteria;    Escherichia Coli;    Salmonella typhimurium;    Fourier transform infrared spectroscopy;    X-ray diffraction;    dynamic light scattering;    Fe3O4;    Ag;   

DOI  :  10.1049/mnl.2018.5491

学科分类：计算机科学（综合）

来源: Wiley

【 摘 要 】

Combination therapy with a dipeptidyl peptidase–4 inhibitor and metformin or metformin+ glibenclamide results in substantial and additive glucose- lowering effects in Iraqis patients with type 2 diabetes mellitus . This study evaluated the glycemic control by using two groups of  combinations of drugs metformin + glibenclamide and metformin + sitagliptin in Baghdad teaching hospital / medical city. 68 T2DM patients and 34 normal healthy individuals as control group were enrolled in this study and categorized in to two treatment groups. The group 1 (34 patients ) received ( metformin 500 mg three times daily + glibenclamide 5 mg twice daily ) and the group 2 (34 patients) received (metformin 500 mg three times daily + sitagliptin 100 mg once daily ). From each patients 5 ml of  blood was obtained by veinpuncture and the serum was separated and used for estimating plasma glucose level (FPG,PPG) and HbA1c.The mean fasting plasma glucose and postprandial plasma glucose  significantly lower for group 2 patients for 3 and 6 months of treatment (129.02 ± 1.96 and  118.4 ± 1.33), (159.38 ± 4.72 and  123.88 ± 2.41 mg / dl)  respectively for fasting plasma glucose and postprandial plasma glucose respectively than in group 1 patients  (150.76  ± 3.97  and 127.79 ±2.52) ,(173.25 ± 7.99 respectively  and 140.67 ± 4.66 mg / dl) for fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) respectively. The mean HbA1c % significantly lower for group 2 patients for 3 and 6 months of treatment (6.12 ± 0.091and  5.83 ± 0.083 ) respectively compared  to group 1 patients (7.1 ± 0 .63 and 6.81 ± 0.12 ). In conclusion , the combination of metformin + sitagliptin improved fasting plasma glucose , postprandial plasma glucose  & HbA1c %  in comparison with metformin + glibenclamide combination.

【 授权许可】

CC BY|CC BY-ND|CC BY-NC|CC BY-NC-ND